References
- Mócsai A, Kovács L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014 Mar 13;12(43). doi: 10.1186/1741-7015-12-43
- European Medicines Agency. Biosimilar medicines: Overview. 2023 [cited 2023 Feb 2]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview
- Gimeno-Gracia M, Gargallo-Puyuelo CJ, Gomollón F. Bioequivalence studies with anti-TNF biosimilars. Expert Opin Biol Ther. 2019 Oct;19(10):1031–1043. doi: 10.1080/14712598.2019.1561851
- Chingcuanco F, Segal JB, Kim SC, et al. Bioequivalence of biosimilar tumor necrosis factor-α inhibitors compared with their reference biologics: a systematic review. Ann Intern Med. 2016 Oct 18;165(8):565–574. doi: 10.7326/M16-0428
- Singh I, Patel A, Patel R, et al. Pharmacokinetic and pharmacodynamic bioequivalence study of a pegfilgrastim biosimilar INTP5 in healthy subjects. Cancer Chemother Pharmacol. 2018 Aug;82(2):329–337.
- Mestre-Ferrandiz J, Czech M, Smolen JS, et al. Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective. Expert Rev Pharmacoecon Outcomes Res. 2023;24(2):237–250. doi: 10.1080/14737167.2023.2297926.
- Cornes P. The innovation opportunity. 2021. [updated 2021 Jan; cited 2023 Jan 28]. Available from: https://www.pharmatimes.com/magazine/2021/januaryfebruary_2021/the_innovation_opportunity
- Troein P, Newton M, Scott K. The impact of biosimilar competition in Europe. 2020 [ updated 2020 Dec; cited 2023 Jun 27]. updated 2020 Dec: https://health.ec.europa.eu/system/files/2021-01/biosimilar_competition_en_0.pdf
- Generics and Biosimilars Initiative. Patent expiry dates for biologicals: 2018 update. 2019 [updated 2019 Feb 7; cited 2023 Feb 7]. Available from: http://gabi-journal.net/patent-expiry-dates-for-biologicals-2018-update.html
- Mestre-Ferrandiz J, Palaska C, Kelly T, et al. An analysis of orphan medicine expenditure in Europe: is it sustainable? Orphanet J Rare Diseases. 2019 Dec 11;14(1):287. doi: 10.1186/s13023-019-1246-7
- Niazi SK. The coming of age of biosimilars: a personal perspective. Biologics. 2022;2(2):107–27. doi:10.3390/biologics2020009
- IQVIA. Assessing the biosimilar void: achieving sustainable levels of biosimilar competition in Europe. 2023 [updated 2023 Oct; cited 2023 Dec 8]. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/assessing-the-biosimilar-void
- Barbier L, Simoens S, Soontjens C, et al. Off-patent biologicals and biosimilars tendering in Europe—a proposal towards more sustainable practices. Pharmaceuticals (Basel). 2021 May 24;14(6):499. doi: 10.3390/ph14060499
- Barbier L, Vandenplas Y, Boone N, et al. How to select a best-value biological medicine? A practical model to support hospital pharmacists. Am J Health Syst Pharm. 2022 Nov 7;79(22):2001–2011. doi: 10.1093/ajhp/zxac235.
- Jongsma MME, Aardoom MA, Cozijnsen MA, et al. First-line treatment with infliximab versus conventional treatment in children with newly diagnosed moderate-to-severe crohn’s disease: an open-label multicentre randomised controlled trial. Gut. 2022 Jan;71(1):34–42.
- Wood EM, Hughes DA. The new and non-transparent cancer drugs fund. PharmacoEconomics. 2020 Jan;38(1):1–4. doi: 10.1007/s40273-019-00871-9
- NHS England. Cancer drugs fund list 2021. [ updated 2023 Jun 22; cited 2023 Jun 27]. Available from: https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
- Hawkes N. New cancer drugs fund keeps within £340m a year budget. BMJ. 2018 Jan 29;360:k461. doi: 10.1136/bmj.k461
- NHS England. Innovative medicines fund. 2023 [cited 2023 Jun 27]. Available from: https://www.england.nhs.uk/medicines-2/innovative-medicines-fund/
- Krzyzanowski J. Poland: new bill on the medical fund amending certain reimbursement regulations. 2020. [ updated 2020 Jul 21; cited 2023 Jun 27]. updated: https://insightplus.bakermckenzie.com/bm/investigations-compliance-ethics/poland-new-bill-on-the-medical-fund-amending-certain-reimbursement-regulations
- Emery P, Vencovsky J, Sylwestrzak A, et al. A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2017 Jan;76(1):51–57.
- Girolomoni G, Feldman SR, Emery P, et al. Comparison of injection-site reactions between the etanercept biosimilar SB4 and the reference etanercept in patients with rheumatoid arthritis from a phase III study. Br J Dermatol. 2018 Mar;178(3):e215–e216.
- Shah-Manek B, Baskett A, Baynton E, et al. Perceptions of biosimilars across physician specialities in Europe. Value Health. 2018;21:S265. doi: 10.1016/j.jval.2018.04.1771
- European Medicines Agency. Biosimilar medicines can be interchanged. 2022 [updated 2022 Sep 19; cited 2023 Jun 27]. Available from: https://www.ema.europa.eu/en/news/biosimilar-medicines-can-be-interchanged.
- Barbier L, Vulto AG. Interchangeability of biosimilars: overcoming the final hurdles. Drugs. 2021 Nov;81(16):1897–903. doi: 10.1007/s40265-021-01629-4
- Schiestl M, Krendyukov A. The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information. ESMO Open. 2017;2(3):e000245. doi: 10.1136/esmoopen-2017-000245.
- Danese S, Fiorino G, Raine T, et al. ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis. 2017 Jan;11(1):26–34. doi: 10.1093/ecco-jcc/jjw198.
- Digestive Cancers Europe. Biosimilars education. 2021 [cited 2023 Jul 28]. Available from: https://biosimilars.education.digestivecancers.eu/
- International Alliance of Patients’ Organizations. The global voice for patient-centered healthcare. 2023 [cited 2023 Dec 8]. Available from: https://www.iapo.org.uk/biosimilars-toolkit
- Moorkens E, Vulto AG, Huys I. Biosimilars in Belgium: a proposal for a more competitive market. Acta Clin Belg. 2021 Dec;76(6):441–452. doi: 10.1080/17843286.2020.1761690
- GBMA Education. Biosimilar hub. 2022 [cited 2023 Jun 27]. Available from: https://biosimilarhub.com.au/
- Bachu RD, Abou-Dahech M, Balaji S, et al. Oncology biosimilars: new developments and future directions. Cancer Rep (Hoboken). 2022 Nov;5(11):e1720.
- Joszt L. Ophthalmologists see promise and peril, but lack familiarity, with biosimilars. American Journal of Managed Care. 2022 [updated 2022 Jul 19; cited 2023 Jun 27]. Available from: https://www.ajmc.com/view/ophthalmologists-see-promise-and-peril-but-lack-familiarity-with-biosimilars
- Aitken M, Tewary V, Abouzid A. Unlocking biosimilar potential: learnings from physicians across therapy areas. 2023 [updated 2023, Apr; cited 2023 Apr 28]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/unlocking-biosimilar-potential/iqi-unlocking-biosimilar-potential-04-23-forweb.pdf
- Drelichman G, Castaneda-Hernandez G, Cem Ar M, et al. The road to biosimilars in rare diseases – ongoing lessons from gaucher disease. Am J Hematol. 2020 Mar;95(3):233–237.
- Vulto AG, Vanderpuye-Orgle J, van der Graaff M, et al. Sustainability of biosimilars in Europe: a delphi panel consensus with systematic literature review. Pharmaceuticals (Basel). 2020 Nov 17;13(11):400. doi: 10.3390/ph13110400
- Aitken M, Rodríguez I, Diamantara J, et al. Advancing biosimilar sustainability in Europe: a multi-stakeholder assessment. 2018 [updated 2018 Sep 4; cited 2023 Jun 27]. Available from: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/advancing-biosimilar-sustainability-in-europe.pdf?_=1671113499133
- Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019 Aug 1;21(8):E668–78.
- Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020 Apr;34(2):159–170. doi: 10.1007/s40259-019-00395-w.
- Cornes P, Gascon P, Vulto AG, et al. Biosimilar pegfilgrastim: improving access and optimising practice to supportive care that enables cure. BioDrugs. 2020 Jun;34(3):255–263.
- Barcina Lacosta T, Vulto AG, Turcu-Stiolica A, et al. Qualitative analysis of the design and implementation of benefit-sharing programs for biologics across Europe. BioDrugs. 2022 Mar 01;36(2):217–229.
- National Institute for Health and Care Excellence. Health technologies adoption programme. Introducing biosimilar versions of infliximab: Infectra and Remsima. 2015 [updated 2015 Jul 31;cited 2023 Jun 27]. Available from: https://www.biosimilars-nederland.nl/wp-content/uploads/2015/08/NICE-Adoption-Resource-Biosimilar-Infliximab-2015_07_31.pdf
- Moorkens E, Lacosta TB, Dawoud D, et al. A systematic literature review of gaps and challenges in value assessment of biosimilars: an ISPOR special interest group report. Value Health. 2023 Aug;26(8):1137–1144.
- Ascef BO, Lopes ACF, de Soarez PC. Health technology assessment of biosimilars worldwide: a scoping review. Health Res Policy Syst. 2020 Aug 26;18(1):95.
- Balijepalli C, Desai K, Yan K, et al. PNS278 a review of health technology assessment guidelines on the approval of biosimilars. Value Health. 2019;22:S810. doi: 10.1016/j.jval.2019.09.2178
- Mestre-Ferrandiz J, Towse A. What is the role of HTA for biosimilars? 2014 [updated 2014 Jan 4; cited 2023 Jun 27]. Available from: https://www.ohe.org/publications/what-role-hta-biosimilars/
- National Institute for Health and Care Excellence. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy. 2015 [ updated 2015 Feb 25; cited 2023 May 30]. updated: https://www.nice.org.uk/guidance/ta329/chapter/1-Guidance
- European Medicines Agency. Remsima. Summary of product charateristics. 2013 [ updated 2023 May 30; cited 2023 May 30]. updated: https://www.ema.europa.eu/en/documents/product-information/remsima-epar-product-information_en.pdf
- National Institute for Health and Care Excellence. NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis. 2021 [ updated 2021 Jun 10; cited 2023 Jun 27]. updated: https://www.nice.org.uk/news/article/nice-recommends-several-treatment-options-to-help-thousands-with-moderate-rheumatoid-arthritis
- Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021 Oct;43(5):1251–1256. doi: 10.1007/s11096-021-01243-0
- Bonetti A, Giuliani J. Implications of drugs with rebate in Europe. Lancet Reg Health Eur. 2021 Apr;3:100060. doi: 10.1016/j.lanepe.2021.100060
- Giuliani J, Bonetti A. The economic impact of biosimilars in oncology and hematology: the case of trastuzumab and rituximab. Anticancer Res. 2019 Jul;39(7):3971–3973. doi: 10.21873/anticanres.13552
- Giuliani J, Fiorica F, Albanese V, et al. Financial toxicity and cancer treatments: help from biosimilars – the explanatory case of bevacizumab. Eur J Cancer. 2021 Jan;143:40–42.
- Kurki P, Barry S, Bourges I, et al. Safety, immunogenicity and interchangeability of biosimilar monoclonal antibodies and fusion proteins: a regulatory perspective. Drugs. 2021 Nov;81(16):1881–1896.